Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid

Amyloid Angiopathy Clinical Trial

Official title:

Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03262246
• Other study ID #: ISAAC
• Status: Completed
• Start date: June 2, 2016
• Est. completion date: December 31, 2018

Study information

• Verified date: August 2018
• Source: Groupe Hospitalier Paris Saint Joseph
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The cerebral amyloïd angiopathy ( AAC) is a disease characterized by deposits of beta-amyloid peptids in the walls of the arteries of young and average calibre of the brain and the leptomeninx. The incidence of the AAC increases strongly with the age and represents a major cause of spontaneous brain haemorrhage to people over 60. The main demonstration is the lobar brain haemorrhage, the other ones are bleedings under arachnoid cortical and microbleedings leading to cognitive decline.

Anatomical studies reported the presence of cortical infarcts in patients having amyloïd deposits suggesting an association between asymptomatic cortical cerebral infarcts and AAC.

However prevalence and meaning of these infarcts in patients having an AAC remain badly known because of studies on low number of patients and the rarity of radiological analyses of these infarcts .A better knowledge of these asymptomatic cortical infarcts would allow to dread better cognitive disorders(confusions) presented by these patients, and to develop preventive strategies.

Besides, the risk factors of severity of the AAC are little studied.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 126
• Est. completion date: December 31, 2018
• Est. primary completion date: December 31, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• age>55

• hospitalized in CAEN hospital and Paris St Joseph Hospital between 1st january 2011 and 31 december 2015 for cerebral haemorrhage with MRI images diagnosing cerebral amyloid angiopathy.

Exclusion Criteria:

• Insufficient MRI images quality without FLAI sequence, T2 GRE

• disease with same radiologic and clinical signs that cerebral amyloid angiopathy.

Related Conditions & MeSH terms

• Amyloid Angiopathy
• Amyloidosis
• Cerebral Infarction
• Infarction

Intervention

Other:
• medical report consultation
investigators consult medical report concerning patient identified for cerebral amyloid angiopathy

Locations

Country	Name	City	State
France	Groupe Hospitalier Paris Saint Joseph	Paris	Ile-de-France

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of patient with cerebral infarction and associated factors in a cohort of cerebral amyloid angiopathy patients		1day